Literature DB >> 19420810

Increased risk of renal deterioration associated with low e-GFR in type 2 diabetes mellitus only in albuminuric subjects.

Shu Meguro1, Toshikatsu Shigihara, Yusuke Kabeya, Masuomi Tomita, Yoshihito Atsumi.   

Abstract

OBJECTIVE: The significance of estimated glomerular filtration rate (e-GFR) in diabetic nephropathy has yet to be clearly determined. We therefore compared albuminuria and e-GFR for usefulness in predicting progressive decline in renal function.
METHODS: A total of 1,303 subjects with type 2 diabetes mellitus whose e-GFR was more than 30 mL/min/1.73 m(2) were followed for three years. Associations of clinical staging based on AER and that based on e-GFR with progression of renal insufficiency (e-GFR <30 mL/min/1.73 m(2)) were evaluated.
RESULTS: On univariate analysis, both clinical stages based on e-GFR and AER were significant variables (p<0.05). On multiple logistic regression analysis, the odds ratio for macroalbuminuria was 132.3, and that for microalbuminuria was 10.3 while that for e-GFR less than 60 mL/min/1.73 m(2) was 9.0 for further deterioration of renal function. On the other hand, subjects without albuminuria exhibited a rate of disease progression of less than 1% irrespective of e-GFR level.
CONCLUSIONS: Both albuminuria and reduced e-GFR are significant and independent risk factors for further deterioration of diabetic nephropathy, though albuminuria had a greater odds ratio than reduced e-GFR for deterioration of renal function over a three-year period. e-GFR exhibited additive risk for deterioration of diabetic nephropathy within three years only when albuminuria was present.

Entities:  

Mesh:

Year:  2009        PMID: 19420810     DOI: 10.2169/internalmedicine.48.1865

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  6 in total

Review 1.  Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT.

Authors:  Toni Terry; Kalyani Raravikar; Nalurporn Chokrungvaranon; Peter D Reaven
Journal:  Curr Cardiol Rep       Date:  2012-02       Impact factor: 2.931

2.  Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.

Authors:  Faramarz Ismail-Beigi; Timothy Craven; Mary Ann Banerji; Jan Basile; Jorge Calles; Robert M Cohen; Robert Cuddihy; William C Cushman; Saul Genuth; Richard H Grimm; Bruce P Hamilton; Byron Hoogwerf; Diane Karl; Lois Katz; Armand Krikorian; Patrick O'Connor; Rodica Pop-Busui; Ulrich Schubart; Debra Simmons; Harris Taylor; Abraham Thomas; Daniel Weiss; Irene Hramiak
Journal:  Lancet       Date:  2010-06-30       Impact factor: 79.321

3.  One-year estimated glomerular filtration rate decline as a risk factor of cardiovascular and renal end-points in high-risk Japanese patients.

Authors:  Shu Meguro; Jun Inaishi; Yasunori Sato; Issei Komuro; Hiroshi Itoh
Journal:  J Diabetes Investig       Date:  2020-12-30       Impact factor: 4.232

4.  Factors Associated with the Decline of Kidney Function Differ among eGFR Strata in Subjects with Type 2 Diabetes Mellitus.

Authors:  Shu Meguro; Masuomi Tomita; Yusuke Kabeya; Takeshi Katsuki; Yoichi Oikawa; Akira Shimada; Toshihide Kawai; Hiroshi Itoh; Yoshihito Atsumi
Journal:  Int J Endocrinol       Date:  2012-12-18       Impact factor: 3.257

5.  More impact of microalbuminuria on retinopathy than moderately reduced GFR among type 2 diabetic patients.

Authors:  Yu-Hsin Chen; Harn-Shen Chen; Der-Cherng Tarng
Journal:  Diabetes Care       Date:  2012-02-14       Impact factor: 19.112

6.  Past Obesity as well as Present Body Weight Status Is a Risk Factor for Diabetic Nephropathy.

Authors:  Shu Meguro; Yusuke Kabeya; Karin Tanaka; Toshihide Kawai; Masuomi Tomita; Takeshi Katsuki; Yoichi Oikawa; Yoshihito Atsumi; Akira Shimada; Masami Tanaka; Junichiro Irie; Yoshifumi Saisho; Hiroshi Itoh
Journal:  Int J Endocrinol       Date:  2013-08-26       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.